Literature DB >> 15890270

Gastric cancer.

Vincenzo Catalano1, Roberto Labianca, Giordano D Beretta, Gemma Gatta, Filippo de Braud, Eric Van Cutsem.   

Abstract

Gastric cancer is one of the most common cancers and one of the most frequent causes of cancer-related deaths. The incidence, diagnostic studies, and therapeutic options have undergone important changes in the last decades, but the prognosis for gastric cancer patients remains poor, especially in more advanced stages. Surgery is the mainstay of treatment of this disease, even if it is associated with a high rate of locoregional and distant recurrence. There is ongoing debate regarding the role of adjuvant treatment In advanced disease, palliation of symptoms, rather than cure, is the primary goal of patient management. Several combination therapies have been developed and have been examined in phase III trials; however, in most cases, they have failed to demonstrate a survival advantage over the reference arm. This review summarizes the most important recommendations for the management of patients with gastric cancer.

Entities:  

Mesh:

Year:  2005        PMID: 15890270     DOI: 10.1016/j.critrevonc.2005.01.002

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  34 in total

1.  Quantitative proteomics discloses MET expression in mitochondria as a direct target of MET kinase inhibitor in cancer cells.

Authors:  Tiannan Guo; Yi Zhu; Chee Sian Gan; Sze Sing Lee; Jiang Zhu; Haixia Wang; Xin Li; James Christensen; Shiang Huang; Oi Lian Kon; Siu Kwan Sze
Journal:  Mol Cell Proteomics       Date:  2010-08-16       Impact factor: 5.911

2.  Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients.

Authors:  Jing-Ting Jiang; Yue-Ping Shen; Chang-Ping Wu; Yi-Bei Zhu; Wen-Xiang Wei; Lu-Jun Chen; Xiao Zheng; Jing Sun; Bin-Feng Lu; Xue-Guang Zhang
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

3.  Accomplishments in 2008 in the management of advanced gastroesophageal cancer.

Authors:  Salah-Eddin Al-Batran; Jaffer A Ajani
Journal:  Gastrointest Cancer Res       Date:  2009-09

Review 4.  Impact of clinicopathological parameters on survival after multiorgan resection among patients with T4 gastric carcinoma: a systematic review and meta-analysis.

Authors:  G Zu; T Zhang; W Li; Y Sun; X Zhang
Journal:  Clin Transl Oncol       Date:  2017-01-04       Impact factor: 3.405

5.  Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status.

Authors:  Hyeong Su Kim; Jung Han Kim; Hee Jun Kim; Hyun Joo Jang; Jin Bae Kim; Ji Won Kim; So Young Jung; Byung Chun Kim; Dae Hyun Yang; Soah Park; Keong Ju Kim; Soon Il Lee; Dae Young Zang
Journal:  Oncol Lett       Date:  2011-11-25       Impact factor: 2.967

6.  The Serum Immunoglobulin G Glycosylation Signature of Gastric Cancer.

Authors:  L Renee Ruhaak; Donald A Barkauskas; Javier Torres; Cara L Cooke; Lauren D Wu; Carol Stroble; Sureyya Ozcan; Cynthia C Williams; Margarita Camorlinga; David M Rocke; Carlito B Lebrilla; Jay V Solnick
Journal:  EuPA Open Proteom       Date:  2015-03-01

7.  Influence of excess body weight on the surgical outcomes of total gastrectomy.

Authors:  Daisuke Nobuoka; Naoto Gotohda; Yuichiro Kato; Shinichiro Takahashi; Masaru Konishi; Taira Kinoshita
Journal:  Surg Today       Date:  2011-07-12       Impact factor: 2.549

8.  Serum glycan signatures of gastric cancer.

Authors:  Sureyya Ozcan; Donald A Barkauskas; L Renee Ruhaak; Javier Torres; Cara L Cooke; Hyun Joo An; Serenus Hua; Cynthia C Williams; Lauren M Dimapasoc; Jae Han Kim; Margarita Camorlinga-Ponce; David Rocke; Carlito B Lebrilla; Jay V Solnick
Journal:  Cancer Prev Res (Phila)       Date:  2013-12-10

9.  Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor progression and lymphogenous metastasis.

Authors:  Weijie Yuan; Zhikang Chen; Shaobin Wu; Jie Ge; Shi Chang; Xianwei Wang; Jingxiang Chen; Zihua Chen
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

10.  Irinotecan, leucovorin and 5-fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer.

Authors:  Jung Han Kim; Hyeong Su Kim; A Rum Han; In Ho Moh; Doo Cheol Chung; Dae Ro Choi; Hyun Joo Jang; Jin Bae Kim; Dae Hyun Yang; Soon Il Lee; Dae Young Zang
Journal:  Oncol Lett       Date:  2012-07-02       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.